Anna Zhao

Anna Zhao has more than 10 years’ experience in practicing law in the life sciences field in the U.S. and China. She previously practiced in an international law firm in their Beijing and Washington D.C. offices for a decade and has rich experience working with both established and emerging pharmaceutical companies on the U.S. FDA and China NMPA regulatory, corporate, and transactional matters. Drawing her Chinese background and cross-border regulatory and transactional experience, Anna is well positioned to advise on clinical trials, manufacturing, drug promotion, marketing, post-marketing compliance and related corporate and commercial transactions.

Anna is a member of the New York State Bar, Washington D.C. Bar and is qualified to practice the Chinese law. She has authored several articles, including Legal and Ethical Considerations for Offering Clinical Trial Recruitment Payments and Enrollment Incentives (Update Magazine), and What’s the Future of Marketing Applications Based Solely on Foreign Clinical Trial Data? (Food and Drug Law Journal, Issue 79-1). She currently serves on the Food and Drug Law Institute's peer review committee and is active in the U.S. and China life sciences legal communities.